Lixisenatide vs Liraglutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Adlyxin, Lyxumia
Lixisenatide is a short-acting, once-daily GLP-1 agonist for type 2 diabetes, discovered by Zealand Pharma and sold by Sanofi as Adlyxin (US) and Lyxumia (EU). It never caught on against weekly GLP-1 drugs, and it has mostly left the market: standalone Adlyxin was discontinued in the US with last availability around January 2023, and the EU authorisation for Lyxumia was withdrawn in December 2025. It lives on in Soliqua 100/33, a fixed combination with insulin glargine.
Also: Victoza, Saxenda
Liraglutide is a once-daily injectable GLP-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone GLP-1 but is engineered with a fatty acid chain so it survives in the body far longer. It is FDA-approved as Victoza for type 2 diabetes (2010) and as Saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. As of 2024 a generic version is also FDA-approved.
Key Comparison Insights
- Both Lixisenatide and Liraglutide are FDA approved medications.
- Lixisenatide is categorized as Metabolic, while Liraglutide is Weight Loss.
Detailed Comparison
| Attribute | Lixisenatide | Liraglutide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Lixisenatide is a 44-amino-acid peptide based on exendin-4, with the C-terminus modified by a string of lysines. It activates the GLP-1 receptor to boost insulin release when glucose is high, lower glucagon, and slow stomach emptying. Because it is short-acting (terminal half-life about 3 hours), its strongest effect is on the blood sugar spike after the meal following the injection, rather than round-the-clock glucose. That is why it pairs well with basal insulin, which handles fasting glucose while lixisenatide covers the post-meal rise. It has only a small effect on body weight compared with modern long-acting GLP-1s. | Liraglutide binds the GLP-1 receptor, the same target as the body's own incretin hormone. The clever part is glucose-dependence: it tells the pancreas to release insulin only when blood sugar is high, and it dials down glucagon (the hormone that raises blood sugar), so it lowers glucose without the crashing lows that older diabetes drugs can cause. It also slows how fast the stomach empties, which blunts post-meal sugar spikes and keeps you full longer. In the brain, it acts on GLP-1 receptors in the hypothalamus to turn down hunger signals and turn up satiety, which is the main driver of the weight loss seen with Saxenda. |
| Common Dosing | 20 mcg once daily (after 10 mcg for 14 days) Once daily | 1.8-3 mg daily Once daily |
| Administration | Subcutaneous injection within one hour before the first meal of the day | Subcutaneous injection daily |
| Typical Duration | Long-term for type 2 diabetes | Long-term / chronic use |
| Best Time to Take | Within one hour before the first meal of the day | Morning or evening, consistent daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The FDA approved Adlyxin in July 2016 for adults with type 2 diabetes, based on the GetGoal trial program. The key safety study, ELIXA (NEJM 2015), randomized 6,068 people with type 2 diabetes and a recent acute coronary syndrome: cardiovascular events were 13.4% on lixisenatide versus 13.2% on placebo (hazard ratio 1.02). So it was proven safe for the heart, but unlike liraglutide, semaglutide or dulaglutide it showed no heart benefit. In trials nausea hit about 25% of users versus 6% on placebo. Soliqua 100/33 (insulin glargine plus lixisenatide) was approved in November 2016. Outside diabetes, the LIXIPARK trial (NEJM 2024, 156 people with early Parkinson's) found less worsening of motor symptoms over 12 months on lixisenatide than placebo, an intriguing signal that needs bigger trials, with frequent nausea as the trade-off. Commercially, Sanofi pulled standalone Adlyxin in the US and requested EU withdrawal of Lyxumia (December 2025) for business reasons, not safety. | This is not a gray-area research peptide. Liraglutide has been through large, gold-standard human trials. The LEADER trial randomized 9,340 high-risk type 2 diabetes patients and found liraglutide cut the rate of cardiovascular death, heart attack, or stroke versus placebo (13.0% vs 14.9%, published in the New England Journal of Medicine in 2016). For weight, the SCALE program showed adults without diabetes lost roughly 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose, far more than placebo. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, especially during dose escalation. Its labeling carries a boxed warning about thyroid C-cell tumors based on rodent studies, though a clear human link has not been established. In short, the evidence here is strong and human, not preliminary. |
Frequently Asked Questions: Lixisenatide vs Liraglutide
What is the difference between Lixisenatide and Liraglutide?
Lixisenatide is a metabolic peptide that lixisenatide is a short-acting, once-daily glp-1 agonist for type 2 diabetes, discovered by zealand pharma and sold by sanofi as adlyxin (us) and lyxumia (eu). it never caught on against weekly glp-1 drugs, and it has mostly left the market: standalone adlyxin was discontinued in the us with last availability around january 2023, and the eu authorisation for lyxumia was withdrawn in december 2025. it lives on in soliqua 100/33, a fixed combination with insulin glargine. Liraglutide is a weight loss peptide that liraglutide is a once-daily injectable glp-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone glp-1 but is engineered with a fatty acid chain so it survives in the body far longer. it is fda-approved as victoza for type 2 diabetes (2010) and as saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. as of 2024 a generic version is also fda-approved. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Lixisenatide or Liraglutide?
Neither is universally "better" - the choice depends on your specific goals. Lixisenatide is typically used for metabolic purposes, while Liraglutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Lixisenatide and Liraglutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Lixisenatide and Liraglutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.